← Back to Analyst Consensus 
LYEL Buy
Lyell Immunopharma, Inc.
Current Price —
Implied Upside —
Analysts 14
30-Day Momentum
▲ 0 upgrades / ▼ 0 downgrades / 0 reiterations from 0 firms
Next Earnings
Nov 9, 2026 (14 days)
Rating Timeline
| Date ▼ | Firm | Action | From → To Rating | Price Target | Firm Rating |
|---|---|---|---|---|---|
| Sep 11, 2026 | Needham | reiterate | Buy → Buy | — | 50% |
| Aug 6, 2026 | Stifel | initiate | — → Buy | — | 53% |
| Jul 22, 2026 | B. Riley Securities | initiate | — → Buy | — | 55% |
| Jun 15, 2026 | Citizens | reiterate | Market Outperform → Market Outperform | — | 47% |
| Jun 15, 2026 | Needham | reiterate | Buy → Buy | — | 50% |
| Jun 9, 2026 | HC Wainwright & Co. | reiterate | Buy → Buy | — | 44% |
| Jun 8, 2026 | Needham | reiterate | Buy → Buy | — | 50% |
| Jun 3, 2026 | HC Wainwright & Co. | reiterate | Buy → Buy | — | 44% |
| May 7, 2026 | Needham | reiterate | Buy → Buy | — | 50% |
| Apr 10, 2026 | Needham | initiate | — → Buy | — | 50% |
| Mar 9, 2026 | Citizens | initiate | — → Market Outperform | $34 | 47% |
| Dec 9, 2025 | HC Wainwright & Co. | upgrade | Neutral → Buy | $45 | 44% |
| Nov 24, 2025 | HC Wainwright & Co. | maintain | Neutral → Neutral | $20 | 44% |
| Sep 26, 2025 | LUCID CAPITAL MARKETS | initiate | — → Buy | $20 | 32% |
| Jun 24, 2025 | HC Wainwright & Co. | maintain | Neutral → Neutral | $10 | 44% |
| Apr 16, 2025 | HC Wainwright & Co. | reiterate | Neutral → Neutral | $1 | 44% |
| Mar 13, 2025 | HC Wainwright & Co. | reiterate | Neutral → Neutral | $1 | 44% |
| Nov 12, 2024 | HC Wainwright & Co. | reiterate | Neutral → Neutral | $1 | 44% |
| Oct 30, 2024 | B of A Securities | downgrade | Buy → Underperform | $1 | 53% |
| Oct 28, 2024 | HC Wainwright & Co. | reiterate | Neutral → Neutral | $1 | 44% |
| Aug 19, 2024 | HC Wainwright & Co. | reiterate | Neutral → Neutral | $1 | 44% |
| Jun 27, 2024 | B of A Securities | maintain | Buy → Buy | $6 | 53% |
| Jun 27, 2024 | HC Wainwright & Co. | downgrade | Buy → Neutral | $1 | 44% |
| May 7, 2024 | HC Wainwright & Co. | reiterate | Buy → Buy | $6 | 44% |
| Feb 29, 2024 | HC Wainwright & Co. | maintain | Buy → Buy | $6 | 44% |
| Nov 9, 2023 | HC Wainwright & Co. | maintain | Buy → Buy | $8 | 44% |
| Aug 28, 2023 | JP Morgan | downgrade | Overweight → Neutral | $5 | 54% |
| May 5, 2023 | HC Wainwright & Co. | reiterate | — → Buy | $9 | 44% |
| Mar 2, 2023 | HC Wainwright & Co. | maintain | — → Buy | $9 | 44% |
| Jan 24, 2023 | Morgan Stanley | maintain | — → Equal-Weight | $4 | 54% |
| Nov 14, 2022 | Morgan Stanley | downgrade | Overweight → Equal-Weight | $7 | 54% |
| Nov 11, 2022 | Goldman Sachs | downgrade | Buy → Neutral | $0 | 54% |
| Oct 17, 2022 | HC Wainwright & Co. | initiate | — → Buy | $12 | 44% |
| May 24, 2022 | Goldman Sachs | maintain | — → Buy | $12 | 54% |
| Mar 31, 2022 | Goldman Sachs | maintain | — → Buy | $21 | 54% |
| Jan 6, 2022 | Morgan Stanley | maintain | — → Overweight | $20 | 54% |
| Jul 12, 2021 | Morgan Stanley | initiate | — → Overweight | $25 | 54% |
| Jul 12, 2021 | B of A Securities | initiate | — → Buy | $25 | 53% |
| Jul 12, 2021 | JP Morgan | initiate | — → Overweight | $22 | 54% |
| Jul 12, 2021 | Goldman Sachs | initiate | — → Buy | $30 | 54% |
Price Target Trend
May 12, 2026 Oct 26, 2026
EPS Estimates
+1q —
0q —
0y —
+1y —
Cross-Platform Signals
No cross-platform signals in the last 90 days